Mostrar el registro sencillo del ítem

Polimorfismos de la metaloproteasa de matriz 9 (MMP-9) en el diagnóstico del carcinoma prostático. Experiencia preliminar

dc.contributor.authorGil Ugarteburu, Rodrigo
dc.contributor.authorRivas del Fresno, Manuel 
dc.contributor.authorGonzález Rodríguez, Iván
dc.contributor.authorGonzález Arriaga, Patricia 
dc.contributor.authorLópez Cima, María Felicitas 
dc.contributor.authorFernández Somoano, Ana 
dc.contributor.authorFernández García, Isabel
dc.contributor.authorBenito García, Priscila
dc.contributor.authorMuruamendiaraz Fernández, Valentín
dc.contributor.authorTardón García, Adonina 
dc.date.accessioned2017-07-21T07:57:07Z
dc.date.available2017-07-21T07:57:07Z
dc.date.issued2010
dc.identifier.citationArchivos Españoles de Urología, 63(2), p. 125-132 (2010)
dc.identifier.issn1576-8260
dc.identifier.issn0004-0614
dc.identifier.urihttp://hdl.handle.net/10651/43529
dc.description.abstractAbstract Polymorphisms Q279R, P574R and -1562 C/T of matrix metalloproteinase-9 (MMP-9) gene have been linked with the risk of cancer and with tumoral aggressiveness in various types of cancer. So far there are no studies in the literature analysing the link between polymorphisms Q279R, P574R and -1562 C/T of MMP-9 and prostate cancer. OBJECTIVES: To establish the presence of the MMP-9's gene polymorphisms (Q279R, P574R and -1562 C/T)in relation to results of prostate biopsy, PSA values and Gleason score. METHODS: Hospital cohort of 100 patients with suspected prostate cancer, subjected to prostate biopsy, in whom the MMP-9 polymorphisms (Q279R, P574R and -1562 C/T) were analysed using the PCR-RLFP technique. RESULTS: No statistically significant differences were found in the presence of the Q279R, P574R and -1562 C/T polymorphisms in terms of prostate biopsy results (p = 0.264, p = 0.406, p = 0.860, respectively), or Gleason score (p = 0.373, p = 0.367, p = 0.476). Comparing the genotypes of the Q279R, P574R and -1562 C/T polymorphisms resulting from prostate biopsy, using subgroups according to PSA values, no statistically significant differences were found either (p = 0.332 y p = 0.393, respectively ). However, statistically significant differences were found when comparing the genotypes of the -1562 C/T polymorphism of the MMP-9 in patients showing positive biopsy for malignant tumour in comparison to a negative biopsy for a malignant tumour in the subgroup of patients with PSA 10 ng/ml (p=0.049). The joint analysis of the three MMP-9 polymorphisms, using logistical regression study did not reveal any statistically significant differences as far as the risk of developing prostate cancer is concerned based on the presence of the Q279R, P574R and -1562 C/T polymorphisms. CONCLUSION: The Q279R, P574R and -1562 C/T polymorphisms are not linked with the aggressiveness in prostate cancer, neither they are linked to the risk of suffering prostate cancereng
dc.format.extentp. 125-132spa
dc.language.isoengspa
dc.relation.ispartofArchivos Españoles de Urología, 63(2)spa
dc.titlePolimorfismos de la metaloproteasa de matriz 9 (MMP-9) en el diagnóstico del carcinoma prostático. Experiencia preliminarspa
dc.title.alternativeMatrix metalloproteinase- 9 polymorphisms in the diagnosis of prostate cancer. A preliminary experienceeng
dc.typejournal articlespa


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem